Overview of Non-Hodgkin's Lymphoma

Disease-a-Month

Volumn 58, Issue 4, 2012, Pages 208-218

  Guerard, Emily J ^a   Bishop, Michael R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; BENDAMUSTINE; BENZODIAZEPINE DERIVATIVE; BISACODYL; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCUSATE SODIUM; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; FLUORODEOXYGLUCOSE; GRANISETRON; LAXATIVE; ONDANSETRON; PREDNISONE; RITUXIMAB; SENNA EXTRACT; VINCRISTINE;

ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BACTERIAL INFECTION; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTRAST ENHANCEMENT; DIAGNOSTIC PROCEDURE; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; LYMPHADENITIS; LYMPHADENOPATHY; MEMORY CELL; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PLASMA CELL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENNA; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW; CONSTIPATION; HUMANS; LYMPH NODES; LYMPHOMA, NON-HODGKIN; NAUSEA; NEOPLASM STAGING; NEUTROPENIA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; SPINAL PUNCTURE; TOMOGRAPHY, X-RAY COMPUTED; VOMITING;

EID: 84858829378     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2012.01.010     Document Type: Article

References (20)

1. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Martinez-Climent J.A., Fontan L., Gascoyne R.D., et al. Lymphoma stem cells: enough evidence to support their existence?. Haematologica 2010, 95:293-302.
3. Campo E., Swerdlow S.H., Harris N.L., et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
4. Czuczman M.S., Rummel M.J. Clinical roundtable monograph: recent advances in NHL. Highlights from the 51st ASH annual meeting and exposition, December 5-8, 2009, New Orleans, Louisiana. Clin Adv Hematol Oncol 2010, 8:A1-A11.
5. Herrlinger U., Glantz M., Schlegel U., et al. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin Oncol 2009, 36(suppl 2):S25-S34.
6. Dunleavy K., Mikhaeel G., Sehn L.H., et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma 2010, 51(suppl 1):28-33.
7. Armitage J.O. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005, 55:368-376.
8. Shenkier T.N., Voss N., Fairey R., et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002, 20:197-204.
9. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
10. McLaughlin P. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?. Clin Lymphoma Myeloma 2011, 11(Suppl 1):S91-S95.
11. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993, 329:987-994.
12. Staudt L.M. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003, 348:1777-1785.
13. Hesketh P.J. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008, 358:2482-2494.
14. Holland J.F., Scharlau C., Gailani S., et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 1973, 33:1258-1264.
15. Robbins G. Fever in the neutropenic adult patient with cancer, 2008 http://Uptodate.com.
16. Peacock J.E., Herrington D.A., Wade J.C., et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 2002, 137:77-86.
17. Bliziotis I.A., Michalopoulos A., Kasiakou S.K., et al. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2005, 80:1146-1156.
18. Paul M., Borok S., Fraser A., et al. Additional anti-gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005, CD003914.
19. Ng A.K., LaCasce A., Travis L.B. Long-term complications of lymphoma and its treatment. J Clin Oncol 2011, 29:1885-1892.
20. Mahadevan D., Fisher R.I. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011, 29:1876-1884.